Tada

The 9/30/22 MDA on Sedar pp11-15 provides a comprehensive list of APBs clinical achievements and disease fighting benefits. Undoubtedly a blockbuster if it gets to market.

The 9/30/22 financials paint a grim picture. $19,000 in cash, $22,000,000 of current liabilities (including the HEPA debenture due within 1 year), ~ $1.3 mil of monthly operating expenses. The company is in dire straits - out of gas with the pole in sight. 2 late stage clinical trials in the planning stages and looking for $S.  Eversana activities have been suspended pending financing.  RVX issued 1,000,000 restricted stock units in settlement of outstanding compensation. Outstanding Equity instruments now total 314,000,000(p24 of MDA)(1bil = 3.2/sh)

The clock is ticking

Chicagoest